Recently, the clinical application of EGFR TKIs [4], anaplastic lymphoma kinase inhibitors [4], and ROS-associated kinase inhibitors [5, 6] remarkably extended the progression-free survival of NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.